---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000012"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:13:30.403849+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement

## Summary
- Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.
- Cash and equivalents $44.3M at Dec 31, 2025; with private placement net proceeds, runway into H2 2027.
- Private placement raised $20.2M gross from 6.13M shares at $3.25 each; closed March 31, 2026.
- Phase 1 IV rademikibart showed rapid FEV1 improvement in asthma/COPD; Phase 2 Seabreeze STAT topline data expected mid-2026.
- R&D expense increased to $37.8M (FY2025) from $29.3M due to Phase 2 study initiation.

## SEC filing metadata
- accession: 0001835268-26-000012
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/cntb-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000012
- JSON: https://secwatch.observer/filing/0001835268-26-000012.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000012.txt

## Key facts
- Earnings Releases
  Connect Biopharma Holdings Ltd reported financial results for the three and twelve months ended December 31, 2025.
  - Period: the three and twelve months ended December 31, 2025
  - Result: reported results
  source text: On March 31, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.